Hepatitis C virus NS3/4a protease inhibitors

Area of Science:

• Virology
• Medicinal Chemistry
• Drug Discovery

Background:

• Hepatitis C virus (HCV) infection poses a significant global health challenge.
• HCV NS3/4a protease inhibitors have been a primary research focus for two decades.
• Developing effective treatments is crucial for managing HCV infection worldwide.

Purpose of the Study:

• To review the development of HCV NS3/4a protease inhibitors.
• To highlight compounds that have advanced into clinical trials.
• To analyze the design strategies and clinical impact of these inhibitors.

Main Methods:

• Structure-based drug design principles were applied.
• Evolution of inhibitor complexity from peptide to macrocyclic compounds was traced.
• Clinical trial data for advanced compounds were examined.

Main Results:

• Significant advancements in inhibitor potency, resistance management, and pharmacokinetics were achieved.
• Breakthrough structures led to the development of key combination therapies.
• Current combination therapies demonstrate cure rates exceeding 90%.

Conclusions:

• Structure-based design has been instrumental in advancing HCV NS3/4a protease inhibitor development.
• The evolution of these inhibitors has revolutionized HCV treatment.
• Optimized inhibitors are now integral to highly effective HCV combination therapies.